ADC Therapeutics S.A.

NYSE:ADCT

Biotechnology

Healthcare
$1.37 -1.35%

-$0.02 today

Market cap
$192.71M
Beta
1.77
P/E (TTM)
-1.2
EPS (TTM)
-$0.89
52W Low $0.78High $4.98

Volume 1.17M

Average 1.68M

ADCT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

ADC Therapeutics S.A.NYSE: ADCT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $19.88M fell 31.3% year over year, behind the -15.8% change in trailing-twelve-month research & development. Sequentially, it rose 9.3% from the prior quarter. Over 3 fiscal years it compounded at -17.7% a year.

Context

  • Research & development amounted to 127.8% of revenue in FY2025, down 26.9 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -31.3% toward the trailing-twelve-month pace of -15.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.88M+9.3% QoQ
Last fiscal yearDec 2025
$104.01M-5.1% YoY
LTMMar 2026
$94.95M-15.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-31.3%——
1 year-5.1%——
3-year CAGR-17.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
104.01M USD
Year-over-year change
-5.1%
4-year CAGR
-9.9%

Research & Development vs competitors

How ADCT compares with its peers on the latest reported figures

  • ADCT's LTM Mar 2026 research & development of $94.95M is the 6th highest of the 10 companies compared; the peer median is $112.11M.
  • Its year-over-year change of -15.8% is the 6th highest of 10, against a peer median of -11.0%.
  • Research & development amounts to 119.9% of revenue for ADCT, versus a peer median of 305.9%.
ADCT Competitors Peer median
Research & Development for ADCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$346.63M -8.7%+56.3%4685.4%
BCYCBicycle Therapeutics plcLTM Mar 2026$230.13M +16.7%+43.3%362.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$219.98M +42.7%+34.6%249.3%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$162.51M -21.6%+18.9%—
AUTLAutolus Therapeutics plcLTM Mar 2026$112.11M -27.3%+3.1%121.1%
ADCTADC Therapeutics S.A.LTM Mar 2026$94.95M -15.8%-17.7%119.9%
OMEROmeros CorporationLTM Mar 2026$70.57M -39.3%-10.3%713.3%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$58.28M -31.8%+5.0%83.7%
QSIQuantum-Si incorporatedLTM Mar 2026$54.53M -11.0%-9.3%2944.3%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$18.85M +49.9%+8.2%127.5%
Peer median (excluding ADCT) $112.11M-11.0%+8.2%305.9%

Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.92M209.91M69.56M70.84M81.36M
Cost of Revenue1.39M3.3M2.53M5.95M7.67M
Gross Profit32.52M206.61M67.03M64.89M73.68M
Gross Margin95.9%98.4%96.4%91.6%90.6%
Research & Development158M186.46M127.13M109.63M104.01M
Selling, General & Admin136.24M143.49M105.89M85.91M(6.82M)
Operating Expenses294.24M329.95M233.02M195.54M182.06M
Depreciation & Amortization2.63M2.39M3.27M3.28M1.88M
EBITDA(230.54M)(107.7M)(145.83M)(102.65M)(89.27M)
EBITDA Margin-679.7%-51.3%-209.6%-144.9%-109.7%
Operating Income(261.72M)(123.34M)(165.99M)(130.65M)(108.38M)
Operating Margin-771.6%-58.8%-238.6%-184.4%-133.2%
Interest Income66K2.57M10.54M12.27M8.81M
Interest Expense18.34M36.73M46.33M50.21M51.63M
Other Income / Expenses10.22M(33.56M)(34.96M)(27.03M)(34.4M)
Income Before Tax(251.51M)(156.9M)(200.95M)(157.68M)(142.78M)
Pre-Tax Margin-741.5%-74.7%-288.9%-222.6%-175.5%
Income Tax Expense(21.48M)227K39.11M166K(157K)
Net Income(230.03M)(157.13M)(240.05M)(157.85M)(142.62M)
Net Margin-678.2%-74.9%-345.1%-222.8%-175.3%
EPS (Basic)(3.00)(1.99)(2.94)(1.62)(1.12)
EPS (Diluted)(3.00)(1.99)(2.94)(1.62)(1.12)
Weighted Avg Shares76.75M78.15M81.71M97.16M127.07M
Weighted Avg Shares (Diluted)76.75M78.15M81.71M97.16M127.07M

ADC Therapeutics S.A.

NYSE:ADCT

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.